Latest News
Connected Thinking
Leading Voices
Latest News
Calquence (Acalabrutinib) Has an Advantage Over Other BTK Inhibitors in CLL Treatment
Bruton tyrosine kinase (BTK) inhibitors have proven themselves highly effective for both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). The first-generation BTK inhibitor ibrutinib was followed by second-generation drugs such as acalabrutinib (brand name: Calquence), zanubrutinib and tirabrutinib, which have all shown good long-term efficacy and safety.
Learn MorePARP Inhibitors and Recurrent Platinum-Sensitive Ovarian Cancer
Treating Recurrence after PARP Therapy Maintenance therapy with PARP inhibitors is still relatively new There are no clear guidelines yet for how to treat women with platinum-sensitive tumors when they recur after PARP maintenance therapy New trials, such as MEDIOLA, suggest a triplet option Four years ago the FDA approved the first PARP inhibitor (niraparib) […]
Learn MoreBreaking Down the PAOLA Trial — Who Benefits from Olaparib (Lynparza)?
In the PAOLA trial, ovarian cancer patients received either bevacizumab alone or bevacizumab plus olaparib (brand name: Lynparza) after their frontline therapy. “And what they found in this trial was very interesting,” says Dr. John Nakayama, gynecologic oncologist with Allegheny Health Network in Pittsburgh.
Learn MoreThe Pros and Cons of a Patient’s HRD Score
Homologous recombination deficiency (HRD) score is an emerging marker to predict an ovarian cancer patient’s response to PARP inhibitors. However, its use is complicated by a lack of standardization between the molecular diagnostic companies.
Learn MoreDecision Making Around PARP Inhibitors Such as Olaparib (Lynparza) in Frontline Maintenance
The typical treatment for patients with advanced ovarian cancer is surgery plus platinum-based chemotherapy. Although most patients go into remission following this regimen, an estimated 70% relapse within the next three years.
Learn MoreWhy Physicians Should Prioritize Their Emotional Wellbeing
The issue of burnout has long plagued physicians given the many hours of physically and mentally draining work. But the past year of dealing with COVID-19 has ratcheted the demands on doctors even higher, and many may be experiencing profession-related mental health issues for the first time. Now more than ever it's important to pay attention to the idea of compassion fatigue, says Dr. Marianna Strongin, a licensed clinical psychologist and founder of Strong in Therapy, her Manhattan-based private practice.
Learn MoreHow to Find the Right Therapist When You Feel Burned Out — Advice from a Clinical Psychologist
Not surprisingly, doctors tend to be rather picky when choosing professionals to take care of their own health. And that’s true of both physical and emotional health needs. “Doctors happen to be really selective about finding therapists,” says Dr. Marianna Strongin, a licensed clinical psychologist and founder of Strong in Therapy, her Manhattan-based private practice. “I think it’s one of the reasons that they don’t get into therapy earlier.”
Learn MoreFemale Doctors Want the Same Level of Representation – and Respect – as Male Doctors
While male doctors still outnumber female doctors in the United States, the demographic is changing. In 2019, women made up 50.5% of medical school students. Some 80% of doctors age 65 and older are men, who may soon be retiring. In a few years, women may begin to dominate the medical profession. For now, they just want equal treatment from their colleagues.
Learn More